Terminated PHASE3 INTERVENTIONAL NCT00302770

Efficacy of Quetiapine in Generalised Social Anxiety Disorder

Efficacy of Quetiapine in Generalised Social Anxiety Disorder, a Double-blind, Placebo-controlled Study

Sponsor: AstraZeneca

Interventions quetiapine

Updated 5 times since 2017 Last updated: Jan 25, 2011 Started: Jun 30, 2006 Primary completion: Dec 31, 2006 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was terminated due to poor enrollment

Other terminated trials from AstraZeneca

See all terminations from AstraZeneca

A PHASE3 clinical study on Social Anxiety Disorder, this trial is terminated or withdrawn. The trial is conducted by AstraZeneca and has accumulated 5 data snapshots since 2006. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Utrecht, Netherlands